Immuron (IMRN) Non-Current Deferred Tax Liability (2022)
Immuron's quarterly Non-Current Deferred Tax Liability came in at $141141.4 in Q2 2022.
Immuron has reported Non-Current Deferred Tax Liability for 1 years, with the latest figure at $141141.4 in Q2 2022.
- For the quarter ending Q2 2022, Non-Current Deferred Tax Liability changed N/A year-over-year to $141141.4; the trailing twelve-month figure through Jun 2022 stood at $141141.4 (changed N/A YoY), and the FY2022 full-year result was $141141.4, changed N/A from the prior year.
- Non-Current Deferred Tax Liability for Q2 2022 stood at $141141.4.
- The five-year high for Non-Current Deferred Tax Liability was $141141.4 in Q2 2022, with the low at $141141.4 in Q2 2022.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn |
| 10 | Immuron | 1.27 Bn | 1.27 Bn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2022 | 141,141.39 |
| Jun 30, 2022 | 141,141.39 |